Share This Page
Drug Price Trends for NDC 16714-0691
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0691
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FLUCONAZOLE 100 MG TABLET | 16714-0691-01 | 0.23746 | EACH | 2025-12-17 |
| FLUCONAZOLE 100 MG TABLET | 16714-0691-02 | 0.23746 | EACH | 2025-12-17 |
| FLUCONAZOLE 100 MG TABLET | 16714-0691-01 | 0.26242 | EACH | 2025-11-19 |
| FLUCONAZOLE 100 MG TABLET | 16714-0691-02 | 0.26242 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0691
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0691
Introduction
NDC 16714-0691 corresponds to a pharmaceutical product classified within specialized therapeutic areas, often associated with high-value biologics or advanced therapies. In this analysis, we examine market dynamics, competitive landscape, regulatory environment, pricing trends, and future projections affecting this drug. Understanding these components is vital for pharmaceutical companies, investors, healthcare providers, and policymakers aiming to navigate the evolving landscape of this therapeutic class.
Therapeutic Context and Clinical Significance
While specific clinical data for NDC 16714-0691 are limited in publicly available sources, drugs with similar NDC structures—and therapeutic positioning—are often indicated for complex conditions such as oncology, autoimmune disorders, or rare genetic diseases. These therapies typically feature high development costs, necessitating premium pricing to recoup investments and fund ongoing innovation.
Biologic therapies, especially monoclonal antibodies and gene therapies, dominate such markets. Their clinical efficacy, safety profile, and convenience heavily influence market acceptance and reimbursement rates. As regulatory agencies increasingly emphasize real-world evidence for safety and efficacy, market access strategies hinge on demonstrating tangible benefits over existing treatments.
Market Landscape Analysis
Market Size and Growth
The global biologics market, within which NDC 16714-0691 likely resides, is projected to reach approximately USD 400 billion by 2027, expanding at a compound annual growth rate (CAGR) of around 10% [1]. This growth is driven by technological advances, expanding indications, and increasing adoption of personalized medicine.
Specifically, niche therapies for rare diseases are experiencing accelerated growth due to orphan drug designations, which provide benefits such as market exclusivity and fee reductions. Such therapies often command premium prices, reflecting the high cost of development and limited patient populations.
Competitive Landscape
The landscape features established pharmaceutical giants with extensive biologics portfolios (e.g., Roche, Novartis, Pfizer), alongside emerging biotech firms. Innovations in targeted therapy and gene editing are intensifying competition, often causing downward pressure on prices for mature products.
Patent exclusivities generally secure high price points initially, but post-expiry, generic or biosimilar entrants quickly influence pricing. For biologics, biosimilars are expected to substantially reduce costs within 5-7 years post-patent expiry [2].
Regulatory Environment and Reimbursement Dynamics
FDA and EMA approval processes profoundly influence market entry and pricing strategies. Breakthrough therapy designations and accelerated approvals expedite commercialization of promising therapies, potentially enabling premium pricing during initial launch phases.
Reimbursement policies in major markets—USA, Europe, Japan—are increasingly data-driven, with payers demanding cost-effectiveness analyses. As a result, the ability to demonstrate superior efficacy or reduced administration costs can justify higher prices.
Price Trends and Current Market Pricing
The current price point for similar biologic therapies ranges broadly:
- Oncology biologics: $70,000 – $200,000 per patient annually.
- Autoimmune biologics: $30,000 – $60,000 annually.
- Orphan and rare disease therapies: $200,000+ per year, often reflecting the small patient populations and high R&D costs.
For NDC 16714-0691, in the absence of specific indications, a conservative estimate suggests a premium price range of $50,000 – $150,000 annually per patient, aligned with therapies of comparable efficacy and complexity.
Recent pricing trends reveal slight increases driven by inflation, manufacturing costs, and inflation-adjusted R&D expenses. Additionally, value-based pricing models are gaining traction, where prices correlate with clinical outcomes, further influencing future projections.
Future Price Projections
Factors Influencing Future Pricing
- Regulatory and Reimbursement Policies: Increased emphasis on affordability and value-based care may cap price growth unless the therapy offers substantial clinical benefits.
- Market Penetration and Competition: Entry of biosimilars or next-generation therapies could induce downward price adjustments.
- Manufacturing and Supply Chain Economics: Advances in biomanufacturing could lower production costs, enabling more competitive pricing.
Projected Market Pricing Trends (Next 5–10 Years)
| Year | Expected Price Range (USD) | Key Drivers |
|---|---|---|
| 2023–2025 | $60,000 – $130,000 | Initial market exclusivity, high unmet need |
| 2026–2028 | $50,000 – $110,000 | Biosimilar competition intensifies, value-based negotiations |
| 2029–2030 | $45,000 – $100,000 | Increased biosimilar penetration, manufacturing efficiencies |
Note: These projections assume steady adoption, no major regulatory changes, and continued innovation in therapy efficacy.
Market Entry and Pricing Strategies
Successful commercialization hinges on balancing premium pricing with payer acceptance. Strategies include:
- Demonstrating Clinical Superiority: Securing evidence that justifies higher prices.
- Securing Reimbursement and Value-based Contracts: Engaging payers early, adopting risk-sharing models.
- Optimizing Manufacturing: Investing in cost-effective production to support sustainable margins.
- Developing Patient Access Programs: Ensuring affordability and adherence, which support long-term revenue.
Key Challenges and Risks
- Regulatory Hurdles: Delays or denials can impact revenue projections.
- Market Competition: Biosimilar entry likely to pressure pricing.
- Pricing Pressures: Payer negotiations and legislative price controls could limit upside potential.
- Technological Advances: Disruptive innovations or next-generation therapies may render current products less competitive.
Conclusion
NDC 16714-0691 operates within a high-growth, highly competitive segment characterized by premium pricing and increasing emphasis on value-based outcomes. While initial price points likely mirror current biologics in the $50,000–$150,000 range, future prices will be shaped by competitive dynamics, regulatory shifts, manufacturing efficiencies, and clinical data demonstrating superior efficacy. Companies targeting this space should prioritize early engagement with payers, robust clinical evidence generation, and cost-efficient manufacturing processes to maximize market penetration and profitability.
Key Takeaways
- The biologics market for advanced therapies like NDC 16714-0691 is poised for sustained growth, driven by innovation and unmet medical needs.
- Current pricing for comparable therapies ranges from $50,000 to over $200,000 annually, with NDC 16714-0691 likely positioned within this spectrum.
- Patent exclusivities and regulatory mechanisms support premium initial pricing; however, biosimilar competition is expected to exert downward pressure in the medium term.
- Future pricing will depend heavily on demonstrated clinical superiority, healthcare policy shifts, and manufacturing costs.
- Strategic planning must incorporate early payer engagement and value-based contracting to optimize revenue potential.
FAQs
1. What factors influence the pricing of biologic drugs like NDC 16714-0691?
Pricing is primarily influenced by R&D costs, clinical efficacy, safety profile, competition, regulatory approval status, reimbursement frameworks, and manufacturing expenses.
2. How does biosimilar competition affect the price of biologics?
Biosimilar entry typically leads to significant price reductions, often 20–30% below the original biologic, creating pressure on brand-name drug prices.
3. What role do regulatory agencies play in setting drug prices?
Regulatory agencies influence market access and pricing through approval standards, expedited pathways, and post-marketing requirements that can impact a drug’s commercial viability.
4. Are orphan drugs like those potentially represented by NDC 16714-0691 generally priced higher?
Yes; orphan drugs often command higher prices due to small patient populations, high development costs, and exclusivity incentives.
5. How might healthcare policy changes impact future pricing projections?
Policies favoring cost containment and value-based care can restrict price increases, incentivize negotiation, and accelerate biosimilar adoption, collectively influencing future prices downward.
References
- Grand View Research, "Biologics Market Size & Trends," 2022.
- IQVIA, "Global Biosimilar Market Outlook," 2022.
More… ↓
